Please Wait a Moment
X

Articles

23Jul

CTS conversion to the Ortho VERSEIA Integrated Processor (VIP) in January 2021

23 Jul, 2020 | Return|

After a thorough and comprehensive review of proposals received from suppliers of viral marker testing platforms and assays, CTS has decided to convert to the Ortho VERSEIA Integrated Processor (VIP) viral marker testing platform and associated assays in January 2021. An exact conversion date will be provided when available. We are confident that the VERSIA system will allow us to continue delivering on our commitment to support our clients in their life-saving mission.

Read all about it on the Communication page by clicking this link: Communications

Related

Exhibiting at AABB Annual Meeting- Booth 732

We sincerely hope to see you at this year’s AABB Annual Meeting in San Antonio, TX on October ...

Read More >

CTS to Implement Donor HLA testing on the Stratec Gemini Instrument

On April 29, 2019, CTS will begin performing Donor-Screen HLA® Class I and II testing on the Str...

Read More >

VP, Scientific Affairs Dr. Marion Lanteri Speaks at Symposium on Alternatives to Donation Deferral

As an organization dedicated to the safety of the world’s blood and plasma supply, Creative Testing...

Read More >

Confirmatory Algorithm and Assay Changes Effective September 30, 2019

On June 13, 2019, CTS provided information regarding the manufacturer’s discontinuation of HIV...

Read More >

Reminder- Check flights and cargo hours for the 4th of July Holiday

As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...

Read More >

Join us for a Babesia webinar!

As communicated on January 21, 2020, CTS will implement the licensed Grifols Babesia test for sample...

Read More >